University of Washington Department of Bioengineering

SEED Therapeutics Discloses Novel Molecular Glue IND Candidate for Cancer at “Targeted Protein Degradation Think Tank” Symposium

Retrieved on: 
Thursday, October 26, 2023

SEED is a subsidiary of BeyondSpring, Inc. (NASDAQ: BYSI), a clinical-stage biopharmaceutical company focusing on developing innovative therapies.

Key Points: 
  • SEED is a subsidiary of BeyondSpring, Inc. (NASDAQ: BYSI), a clinical-stage biopharmaceutical company focusing on developing innovative therapies.
  • According to Dr. Huang, “The SEED TPD Think Tank shared key TPD developments across academia and industry.
  • Their research, insight, and conviction allow SEED to focus and accelerate basic research into a fast-expanding TPD drug pipeline, enabled by our unique ability to identify the right E3.
  • This symposium provided a valuable exchange on new directions, opportunities, and challenges on TPD drug development.

Spectral AI Adds Healthcare Services Leader and Population Health Expert Deepak Sadagopan to Board of Directors

Retrieved on: 
Monday, October 2, 2023

DALLAS, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI; MDAIW) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced the appointment of Deepak Sadagopan, MHCDS, to its board of directors.

Key Points: 
  • DALLAS, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI; MDAIW) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced the appointment of Deepak Sadagopan, MHCDS, to its board of directors.
  • Currently, Mr. Sadagopan is the Chief Operating Officer of Population Health at Providence St. Joseph Health, one of the largest healthcare systems in the U.S., where he leads population health initiatives across the system to transform care.
  • “Deepak brings a wealth of knowledge and relevant experience to Spectral AI as we advance the DeepView® System through late-stage development and launch,” said Wensheng Fan, the Company’s CEO.
  • Deepak’s contributions will enable us to continue to accelerate our work in bringing our technology to doctors and patients in need.

Rice Biotech Launch Pad accelerator aims to rapidly turn medical and health discoveries into cures

Retrieved on: 
Tuesday, September 12, 2023

HOUSTON, Sept. 12, 2023 /PRNewswire/ -- Rice University today introduced the Rice Biotech Launch Pad, a Houston-based accelerator focused on expediting the translation of the university's health and medical technology discoveries into cures. Supported by federal grants and philanthropic gifts, the new accelerator will bring together local researchers with a national network of industry executives, additional funding sources and about 15,000 square feet of accelerator space.

Key Points: 
  • HOUSTON, Sept. 12, 2023 /PRNewswire/ -- Rice University today introduced the Rice Biotech Launch Pad , a Houston-based accelerator focused on expediting the translation of the university's health and medical technology discoveries into cures.
  • The Rice Biotech Launch Pad is the university's first large-scale initiative designed to help advance internally discovered platform technologies from concept to clinical studies and commercialization.
  • "The Rice Biotech Launch Pad will ensure that our faculty and students have the skills, partnerships, tools and support to create technologies that can transform our city and the world," Rice President Reginald DesRoches said.
  • "More importantly, the accelerator will provide a pathway for these creations and discoveries to be turned into medical cures that significantly impact people's lives.

Curi Bio Awarded Over $4.4M in NIH Grants to Advance Translational Science

Retrieved on: 
Wednesday, August 23, 2023

The second initiative will deliver a novel 3D neuromuscular junction used for disease modeling and potency assays for pharmaceuticals and cosmetics.

Key Points: 
  • The second initiative will deliver a novel 3D neuromuscular junction used for disease modeling and potency assays for pharmaceuticals and cosmetics.
  • These grants, the first of their kind received by Curi Bio from the National Center for Advancing Translational Sciences (NCATS), demonstrate the impact that the company's innovative 3D tissue platforms have made in developing new medicines.
  • These latest awards bring the total non-dilutive funding that Curi Bio has received from the NIH to over $12 million.
  • This content is solely the responsibility of Curi Bio and does not necessarily represent the official views of the National Institutes of Health.

OmniAb Announces the Passing of Director Sunil Patel

Retrieved on: 
Monday, August 7, 2023

OmniAb, Inc. (NASDAQ: OABI) announces that Director Sunil Patel passed away suddenly last week.

Key Points: 
  • OmniAb, Inc. (NASDAQ: OABI) announces that Director Sunil Patel passed away suddenly last week.
  • The Board of Directors and leadership of OmniAb extend their deepest condolences to those who loved and cared for Sunil and express their gratitude for Sunil’s many contributions to OmniAb.
  • “It is with profound sadness that we announce Sunil’s passing,” said John Higgins, OmniAb Board Chair.
  • “Sunil was a highly-valued and engaged member of the OmniAb Board of Directors and played an important role driving our investments and strategy.

Tenpoint Therapeutics Launches with $70 Million Series A Financing to Reverse Vision Loss Through Engineered Cell-Based Therapeutics and In Vivo Reprogramming

Retrieved on: 
Wednesday, July 12, 2023

F-Prime and Sofinnova Partners were the founding investors who supported the company’s early operational development and technology expansion.

Key Points: 
  • F-Prime and Sofinnova Partners were the founding investors who supported the company’s early operational development and technology expansion.
  • Based on these foundational achievements, Tenpoint is advancing approaches to generate specialized ocular cell types both ex vivo and in vivo.
  • “Cell-based therapeutics represent an ideal modality for degenerative ocular diseases since most vision loss results from damaged or missing tissue.
  • Vanessa King, PhD, Tenpoint’s founding CEO, led this financing of the company and will continue to support the organization as a strategic advisor.

A-Alpha Bio Welcomes Heidi Hagen to Its Board of Directors

Retrieved on: 
Tuesday, June 27, 2023

SEATTLE, June 27, 2023 /PRNewswire-PRWeb/ -- A-Alpha Bio, a synthetic biology and machine learning company that measures and engineers protein-protein interactions, announced the appointment of Heidi Hagen to their Board of Directors. Hagen will be A-Alpha Bio's first independent board member.

Key Points: 
  • Hagen, Former Chief Technical Officer of Sonoma Biotherapeutics, Joins as A-Alpha's First Independent Board Member
    SEATTLE, June 27, 2023 /PRNewswire-PRWeb/ -- A-Alpha Bio , a synthetic biology and machine learning company that measures and engineers protein-protein interactions, announced the appointment of Heidi Hagen to their Board of Directors.
  • "We are thrilled to welcome Heidi to our Board of Directors," said David Younger, CEO and Co-Founder of A-Alpha Bio.
  • Based in Seattle, Hagen will be on the ground to support and share her expertise and network with the A-Alpha Bio team.
  • "I am excited to join A-Alpha Bio's Board of Directors and collaborate with this dynamic team of biologists, protein engineers, and data scientists," said Hagen.

Ultima Genomics Adds Tenured Strategic and Technology Leadership In Preparation for Commercial Launch

Retrieved on: 
Monday, June 26, 2023

Shlomey Derhi will join the Company's R&D and engineering leadership as Head of Architecture and Integration and will be focused on accelerating technology development of the Company's unique sequencing architecture.

Key Points: 
  • Shlomey Derhi will join the Company's R&D and engineering leadership as Head of Architecture and Integration and will be focused on accelerating technology development of the Company's unique sequencing architecture.
  • "We are excited to have two proven and tenured industry leaders join our leadership team at this important stage of our Company," said Gilad Almogy, CEO and founder of Ultima Genomics.
  • She has deep scientific, technical and commercial expertise and will be instrumental in driving customer success, strategy and commercial focus as we transition from early access to commercial launch.
  • He will be pivotal as we prepare our first product, the UG100™ for commercial launch, and continue to advance our unique sequencing architecture."

Starlight Cardiovascular Appoints Paul G. Yock, MD to its Board of Directors

Retrieved on: 
Tuesday, June 13, 2023

SAN DIEGO, June 13, 2023 /PRNewswire/ -- Paul G. Yock has joined the Starlight Cardiovascular Board of Directors. Dr. Yock is the Founder, Director Emeritus, and a Board Member of the Stanford Byers Center for Biodesign. He is the former Martha Meier Weiland Professor of Medicine, founding co-chair of Stanford University's Department of Bioengineering, and the 2018 recipient of the National Academy of Engineering's Gordon Prize for Innovation in Engineering and Technology Education. Yock, who is trained as an interventional cardiologist, is known for his numerous innovative contributions to medical technology, including the Rapid Exchange angioplasty and stenting system, intravascular ultrasound (IVUS), and the Smart Needle.

Key Points: 
  • SAN DIEGO, June 13, 2023 /PRNewswire/ -- Paul G. Yock has joined the Starlight Cardiovascular Board of Directors.
  • "We are overjoyed that Paul has joined the Starlight family," stated Beverly Tang, co-Founder and CEO of Starlight Cardiovascular.
  • Yock was appointed as an independent director and joins Alf Grunwald, Tom Duerig, and Beverly Tang on the Board of Directors.
  • "Starlight Cardiovascular is taking on this challenge by developing highly novel pediatric technologies -- and, equally important, pioneering novel approaches to business execution.

Walking Fish Therapeutics Expands Leadership Team

Retrieved on: 
Thursday, June 1, 2023

SOUTH SAN FRANCISCO, June 01, 2023 (GLOBE NEWSWIRE) -- Walking Fish Therapeutics, a leader in B cell engineering, today announced the promotion of Julie Kim, PharmD, MS, to Chief Business Officer. In this new position, Dr. Kim will lead Walking Fish’s business development endeavors and coordinate the company’s external alliances and strategic planning processes.

Key Points: 
  • SOUTH SAN FRANCISCO, June 01, 2023 (GLOBE NEWSWIRE) -- Walking Fish Therapeutics, a leader in B cell engineering, today announced the promotion of Julie Kim, PharmD, MS, to Chief Business Officer.
  • “We are delighted to announce the expansion of Julie’s role with Walking Fish,” said Lewis (Rusty) Williams, MD, PhD, co-founder and CEO of Walking Fish Therapeutics.
  • Prior to Walking Fish Therapeutics, she served as Vice President at Quan Capital, responsible for execution and management of biotech investments and served as board observer to several start-up companies, including Walking Fish Therapeutics.
  • Dr. Arvindan joins Walking Fish as Chief Technology Officer, from Spotlight Therapeutics, where he served as Executive Vice President and Chief Technology Officer.